Citations

Clear

3314 citation(s) found for "Do, Alexander".

Female participation in U.S. oncology clinical trials registered on ClinicalTrials.gov from 2008 to 2020.
Perera, Nirosha D. , Bell, Alexander , Stavins, MaKenna A. , Saleki, Massoud , Ionescu, Ruxandra, Wang, Max , Tao, Jacqueline J. , Sarsour, Nadeen , OʼKeefe, Ryan , Pun, Matthew , Takasugi, Jordan M., King, Roderick K., Bellomo, Tiffany R. , Litt, Henry K. , Fattahi, Sayeh , Bell, Alexander, Ionescu, Ruxandra, Shyu, Margaret , Ji, Sunjong , Steinberg, Jecca R , Mahipal, Amit , Turner, Brandon E.

Mayo Clinic

Journal of Clinical Oncology | September 21, 2021 | Volume: 39 | Issue: 28_suppl | Pages: 85-85

10.1200/jco.2020.39.28_suppl.85 Get It

85 Background: Females are thought to be underrepresented in clinical trials, which may lead to care disparities. We characterized female enrollment trends in U.S. oncology trials registered on ClinicalTrials.gov and identified features associated with accurate representation. Methods: We employed a cross-sectional study design with descriptive, logistic regression, and cox regression analyses. We downloaded 270,172 studies registered on the Aggregate Analysis of the ClinicalTrials.gov database from October 1, 2008 to March 9, 2020, excluding non-interventional and reproductive organ specific trials. We then applied cancer/oncology specific Medical Subject Heading terms and manually reviewed the remaining 27,521 trials for true oncology content. Prevalence-corrected estimates for female participation were calculated as the percentage of females among trial participants divided by the percentage of females in the disease population per U.S. Surveillance, Epidemiology, and End Results Program (SEER) data (participation to prevalence ratio [PPR]), with a range between 0.8 and 1.2 reflecting accurate female representation in the trial. Results: Of 26,894 trials meeting eligibility criteria, 9,059 trials were completed in the U.S., 2,499 trials reported completed study status, and only 1,256 trials reported sex. Among 1,256 oncology trials and 229,056 participants, overall female representation was 46.9% (95% CI, 45.4-48.4%). 43% of trials were industry funded, 29% academic, and 28% U.S. government. Females were underrepresented compared to their disease burden in anal canal (PPR 0.21), thyroid (PPR 0.57), stomach (PPR 0.68), kidney (PPR 0.77), and bone (PPR 0.79) cancer trials. They were accurately represented in head and neck (PPR 0.80), lung (PPR 0.84), bladder (PPR 0.85), skin (PPR 0.88), pancreas (PPR 0.88), colon (PPR 0.90), hematologic (PPR 0.91), liver (PPR 1.01), CNS (PPR 1.03), soft tissue (PPR 1.05), and esophagus (PPR 1.05) cancer trials. Accurate representation was significantly associated with industry funding and pancreas cancer trial focus, but not associated with trial type (medical, surgical, radiation, other invasive, other) (Table). Conclusions: Females are underrepresented compared to their disease burden in many solid tumor clinical trials. Stakeholders can look to industry funded and pancreas cancer trials as models of improvement, but must increase female representation in clinical trials to improve cancer care. [Table: see text]
Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients
Johnstone, Jennie , Meade, Maureen O. , Lauzier, François, Duan, Erick , Dionne, Joanna C. , Heels‐Ansdell, Diane , Thabane, Lehana , Lamarche, Daphnée , Zytaruk, Nicole , Mehta, Sangeeta , Dodek, Peter , McIntyre, Lauralyn , Karachi, Tim , Henderson, William R. , Wood, Gordon , Ovakim, Daniel , Herridge, Margaret S. , Granton, John , Wilcox, M. Elizabeth , Goffi, Alberto , Niven, Daniel J. , Lamontagne, François , D’Aragon, Frédérick , St.-Arnaud, Charles, Ball, Ian, Nagpal, Dave , Girard, Martin , Aslanian, Pierre, Charbonney, Emmanuel , Sligl, Wendy , Adhikari, Neill K. J. , Marquis, François, Archambault, Patrick , Khwaja, Kosar , Kristof, Arnold S. , Kutsogiannis, James, Paunovic, Bojan, Reeve, Brenda , Lellouche, François , Hosek, Paul, Tsang, Jennifer , Binnie, Alexandra , Trop, Sébastien, Loubani, Osama , Hall, Richard , Cirone, Robert, Reynolds, Steve, Lysecki, Paul, Golan, Eyal, Cartin‐Ceba, Rodrigo , Cook, Deborah, Group, Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT) Investigators and the Canadian Critical Care Trials, Wallace, Christine, Sobhi, Gita, Johnstone, Jennie, Lauzier, François, Cook, Deborah, Centoanti, John, Lamarche, Daphne, Laupacis, Andreas, Roberts, Robin, Brun‐Buisson, Christian , Reynolds, Steve, Willems, Sue, Sekhon, Tina , Dodek, Peter, Ayas, Najib , Agda, Maria, Alcuaz, Victoria, Ashley, Betty-Jean, Brewer, Kelsey, Palmer, Janice L. , Brown, Glen, Pavan, Mara, Greisdale, Donald, Foster, Denise , Logie, Suzie, Yip, Judy, Auld, F. C., Carney, Gayle, FLEMING, R.Y. Declan, Good, Jennifer, Manhas, Mandeep, Boyd, Karin, Dheere, Jane, Stelfox, Tom, Couillard, Philippe , Doig, Christopher J. , Booth, Joshua , Codan, Cassidy, Ruddell, Stacy, Cameron, C. Blake, Edison, Rhonda, Mina, Breanna, Berthiaume, Luc , Gaudet, Jonathan, Kutsiogiannis, Jim, Chowdhury, Raiyan, Davidow, Jon, Johnston, Curt, Johnston, Richard , Macala, Kim, Marcushamer, Sam, Markland, D., Matheson, Doug, Payton-Gay, Damian, Zygun, David, Hewer, Tayne, Thompson, Pat, Ge, Maggie, Hall, Janny, Matenchuk, Sharon, Baig, Nadia, McCoshen, Lorena, Alexandropoulos, Katrina, Bain, Sherri, Brandt, Michelle , Constable, Cathy, Douglas, K., Maharaj, Shaleen, Travers, Sabrina, Zarychanski, Ryan, Lys, Justin, Marten, Nicole, Bhairo, Audrey, Ferenes, Halyna, Kozak, Beata, Verrier, Debra, McLaughlin, Dawn-Lee, Blouw, Marcus , Smith, Heather , Gutieror, Oliver, Wingfield, Sherri Lynn, Boyle, M A, Hrabi, Debbie, MacDonald, Chantal, Bento, Karen, Davis, Megan , Dechert, William , Longo, Barbara, Mullen, Courtney, Skrzpek, Elysia, Wierenga, Laurenne, Abuzaiter, Wesam, Amorim, Lynda, Bauer, Rosemarie, Damota, Rachel, Ho, Hoang, Macdougall, Nicole, Thornewell, Mary, Tran, Lara , Visocchi, Jennifer, Hosek, Paul, Plaxton, Bill, Armstong, Catherine, Ellis, Janelle, Fisk, Kayla, Gabnouri, Melissa, Gordon, Emilie, Haegens, Rebecca, Halford, Lisa, Hillis, Brooklyn, Jesso, Rebecca, McLaren, Jennifer , McMillan, Elliot, Pelkmans, Mariska, Rekman, Matthew, Sinkovitis, Sylvia, Truong, Monica, White, Michelle C. , Bates, Noah, Bryden-Cromwell, Susan, Cameron, Colleen, Deen, A. Gamal El, DiGiovanni, Sheri, Foss, Anders, Lee, E. H. , MacGregor, Heidi, Galbraith, Esther, McArthur, Robyn, Mcgregor, J., Miller, Keith R. , Morris, Sharon, Parker, Shelley, Smith, Candice A. , Stoglow, Joanna, Tung, Jennifer , Vos, Melissa , Hand, Lori, Klotz, Lisa, Sabev, Alexandra, Savija, Nevena , Guyatt, Paige, Cosentino, Deanna, Lourenco, Diane, Misina, Julie, Berlingieri, Joseph, Skitch, Steven , Campbell, Tracy , Basheer, Hala, Bruder, Kathy, Cheng, Jane, Qureshi, Kaiser, Infantino, C. A. González, Karachi, Timothy, Alghuroba, Mashari, Khaled, Alia , Millen, Tina, Vaisler, Ryan, Biljan, Maya, Cosentino, Deane, Marriott, Brittany, Muscedere, John, Boyd, Gordon, D`Arsigny, Christine, Drover, John, Erb, Jason , Parker, Chris M., Sibley, Stephanie , Boyd, Tracy, Georgescu, Ilinca, Hunt, Miranda , Muscedere, D., Baker, Cathy, Engel, Jennifer, Fleming, Jennifer , Roderick, Lisa, Silk, Shelley, Spencer, Marcy, Tryon, Michelle, Nagpal, Dave, Ball, Ian, Sharpe, Michael D., Bentall, Tracey, Sturt-Smith, Jessica, Ellis, T.M., Muylaert, Mindy, Paczkowski, Cindy, Campbell, Eileen, Imervoski, Susie, Ovsenek, Athena, Rondinelli, Rebecca, Longfield, Teresa, Moyer, Amy, Norris, F. H., Sumpton, Janice, Teterycz, Karina, Lapinsky, Stephen E. , Munshi, Laveena, Brown, Maedean, Giacomino, Brittany, Jakab, Marnie, Kraguiljac, Alan, Shah, Sumesh, Tamberg, E., Cheng, Doret, Han, Andrew , Leung, Holly, Mantas, Ioanna, Rodrigues, Hilary, Wyllie, Andew, Carmargo, Mercedes, Richter, Beverly, Caporuscio, Rita, Falvo, Rachel Kressner, Fleming, Dimitra, Maxwell, Carmelina, Plantic, Karmen, McIntyre, Lauralyn, Pagliarello, Giuseppe, D`Egidio, Gianni, English, Shane, Hartwick, Mike, Hooper, Jonathan C., Kubelik, D., Meggison, Hilary , Patel, Rakesh , Po, Joseph, Rosenberg, Erin, Gomes, Brigette, Leclair, Lianne, Porteous, Rebecca , Reddie, Shawna, Watpool, Irene , Cox, Marianne, Fraser, Kathy, Kuhn, Jennifer, Richard, Susanne, Weir, Sherry, Cardinal, Pierre , Jones, Gwynne, Microys, Sherissa, Sarti, Aimee , Seely, Andrew , Acres, Shelley, Mietitis, Sydney, Montroy, Kaitlyn, Aikens, Wendy, Dugal, Anne-Marie, Soth, Mark, Alhazanni, Waleed, Clarke, France, Copland, Mary, Hoad, Neala, Sheers, M., Takaoka, Alyson, Zytaruk, Nicole, Connolly, Christa, Davis, Denise, Gallinas, Tracy, Lee-Yoo, Jean, Lukinuk, Connie, Musielak, Leia, Pavunkovic, Nancy, Pelayo, Joy, Phillips, Kaitlyn , Pracsovics, Catherine, Raimondo, Julia, Stankus, Vida, Wright, Angela, Young, Crystal , Cirrone, Rob, Kavikondala, Kanthi, Pellerin, Axelle, Tomat, Laura, Carter, Jeff , Jani, J., Yaets, Brendan, Hodder, Jennifer, Khalid, Imrana, Lee, Julie , Salway, Kurtis D., Sandhu, Gyan, Santos, Marlene, Smith, Orla, Wang, Melissa, Dewhurst, Norman, Dowbenka, Ann, Kosinski, Ann, Parsons, Laura, Proceviat, J, Ramonas, Gitana, Yuen, Mae, Amaral, Andre , Fowler, Rob, Scales, Damon C. , Marinoff, Nicole, Pérez, Adic, Wang, Jane , Hatzifilalithis, Katrina, Iazzetta, John, Kolos, Chrys, Quinton, Ingrid, Herridge, Margaret, Archer, Jaimie, Fraser, Brooke , Geen-Smith, Cheryl, Matté, Andrea, Robles, Priscilla, Urrea, Cristian, Ascroft, Jane, Haji, Fatima , Ming, Jie , Suen, Matthew , Walid, Muhammad, Westlund, Jill M., McCredie, Victoria , Wilcox, Elizabeth , Farías, Paulina , Kosky, Barbara, Pugliese, Christina, Stenyk, Lia, Walczak, Karolina, Ae, Kyung, Kaur, Rajvinder , Lui, Jane , Mateo, Sophia, Pham, Nga, Heslegrave, Ronald J. , Panchbhaya, Zaynab, Sharman, Kim, Goel, Rakhi, Kozluk, Kim, Labelle, Julianne, Marsonia, Hina, Scott, Cecillia, Aslanian, P., Bélisle, Sylvain, Denault, André , Guimond, Jean‐Gilles, Halwagi, Antoine, Hebert, Paul L. , Kolan, Christopher, Mancebo, Jordi , Robillard, Nicholas , Benettaib, Fatna, Boumahni, Dounia, Caporuscio, Casey Bourdeau, Cantin, M, Côté-Gravel, Virginy, Ghamraoui, Ali, Lebrasseur, Martine, Courville, Lancelot Legendre, Lorio, S., Madrid, Maria Trinidad, Poitras, Nicole, Rigal, Romain, Salamé, Maya, Tran, V.K., Bacon, Katie, Boudreau, Nathalie , Carvajal, Cecilia, Gauthier, Lyne, Gendron, Julie, Jean, Karine, Laforest, Louise, Lembo, Antonietta, Lim, S. H., Pagé, France, Pelletier, L, Rodrigue, Marie-Christine, Bellemare, Jean-François, Bordeleau, Simon, Drouin, Christine, Duhaime, Benoit, Laberge, Ann, Lechance, Philippe, Deblois, Estel, Dionne, Maude, Lavoie, Lise, Michel, Isabelle, Pépin, A., Poulin, S., Anctil, Sarah, Marchand, Louis-Étienne , Roy, Robin, St-Arnaud, Charles , Quiroz, Héctor, Bérard, Dominique, Leclair, Marc-André, Bolduc, Virginie, Carbonneau, Élaine, Marchand, Joannie, Masse, Marie-Hélène , Cloutier, Sylvie , Guay, M, Morin, Line, Nicolson, J. T., Paquette, Isabelle, Théberge, France, Lamarche, Yoan , LeGuillan, Soazig, Serri, Karim , Verdant, Colin , Beaulieu, Yanick, Bellemare, Patrick, Rico, Philippe, Bernard, Françis , Giasson, Marc, Brunette, Véronique, Cavayas, Alexandros, Lévesque, Émilie, Labikova, Halina, Palacios, Julia , Langlois, Marie-Ève, Williams, Virginie, Nguyễn, Thùy Anh , Phaneuf, Valérie, Wang, Han Tin, Toupin, Francis, Ahern, Stéphane P., Laufer, Brian, Brosseau, Marc, Dul, Pauline, Harvey, Johanne, Inthanavong, Lotthida, Tassy, Danaë, Assayag, Helen, Bachand, M., Bétournay, Marysa, Daoust, Karine, Goyette, Kristine, Lessard, Ariane, Quach, Marceline, Barriault, Danny, Bellemare, David, Boivin, Anick, Breton, S., Cloutier, Ève, Daigle, Marjorie, Delisle-Thibeault, Charles, Giannakouros, Panagiota, Grenier, Stéphanie, Guilbault, Gabrielle, Léger, Caroline, Trembley, Marie-Claude, Gaudreau, Julie, Grégoire, Claire, Labbé, Véronique, Laprise-Rochette, Ariane, Ouellet, Caroline, Samson, Mélanie , Simoneau, Marie-David, Tourcotte, Virginie, Tran, Tuong-Vi, Lellouche, François, Sia, Ying Tung, Simon, Mathieu, Bouchard, Pierre-Alexandre, Lizotte, Patricia, Châteauvert, Nathalie, Grenier, T, Khwaja, Kosar, Deckelbaum, Dan, Gursahaney, Ash, Hornstein, David, Jayaraman, Dev , Razek, Tarek , Salasidis, Robert, Zanelli, Patrizia, Alam, Norine , Doerksen, Tonia, Matte, Gilbert, Robert, Marie‐France, Goldberg, Peter, Hatzakorzian, Roupen , Shahin, Jason , Qureshi, Salman, Campisi, Josie, Botan, Vasilica, Capilnean, Anissa, Corey, A. E., Gagné, Annick, Mian, J N, Normandin, Kathleen, Hall, Rick , Green, Robert, Gillis, Diana, Julien, Lisa, Magennis, Laura, Mitterer, Tamara, Arsenault, Joanna, Bruce-Payne, Kim, Gallant, Patti, Oeckler, Richard A. , Anderson, Brenda J., Liedl, Lavonne M., Meade, Laurie, Weist, Sueanne, Bartoo, Anna, Bauer, Debbie, Brickley, Vince, Bridges, S. Louis , Brunn, G.J., Eickstaedt, Jennifer E., Bergerson, Jill, Showalter, Sandy, Manley, Melissa, Taylor, Robert, Cryton, Margaret, Fowler, K. T., Krause, Katie, O`Brien, Jackie, Tow, Marianne, Ma, John, Moore, Kaitlin MS, Al‐Dawood, Abdulaziz, Tlayjeh, Haytham , Ghanem, Alaaeldien, Hassanien, Ahmad, Sharkawi, Ashraf El, Humaid, Felwa Bin, Alanizi, Hala, Alanizy, Nadyah, Bogami, Njoud Al, Muhaidib, Mohammed, Gramish, Jawaher , Alsomali, Randa, Devera, Nora, Villafranca, M.C. Muñoz, Fowler, Robert , Thabane, Lehana , Lauzier, François, Marshall, John C. , Arabi, Yaseen M. , Surette, M G , English, Shane , Rochwerg, Bram , Stelfox, Henry T. , Muscedere, John , Ball, Ian, Williamson, David R. , Friedrich, Jan O. , Kutsogiannis, Demetrios James , Zarychanski, Ryan , Taylor, Robert, Cook, Deborah, Group, Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT) Investigators and the Canadian Critical Care Trials, Johnstone, Jennie, Lauzier, François, Cook, Deborah, Oczkowski, Simon J. W. , Bowdish, Dawn M. E. , Reynolds, Steve, Dodek, Peter, Ashley, Betty Jean, Palmer, Janice, Sekhon, Mypinder S. , Auld, Fiona, Fleming, R.Y.Declan, Stelfox, Tom, Parhar, Ken Kuljit S. , Cameron, Candice, Martin, Anne , Thompson, Pat, Bagshaw, Sean M. , Brandt, Michelle, Douglas, Kari, Zarychanski, Ryan, Valente, Maria, Olafson, Kendiss P. , Smith, Heather, Abuzaiter, Wesam, Hosek, Paul, Fisk, Kayla M., McLaren, Jennifer, White, Michelle, Deen, Aminah, Lee, Esther, McGregor, Julie, Miller, Keith, Morris, Sharon, Vos, Melissa, Belley‐Côté, Emilie P. , Shaikh, Sameer, Qureshi, Kaiser, Muscedere, John, D`Arsigny, Christine, Maslove, David M. , Fleming, Jennifer, Spencer, Marcy, Nagpal, Dave, Ball, Ian, Bosma, Karen J. , Alexander, Michelle, Norris, Faith, Munshi, Laveena , Grewal, Gagan , McIntyre, Lauralyn, D`Egidio, Gianni, English, Shane, Hooper, Jonathan, Kyeremanteng, Kwadwo , Neilipovitz, David , Cox, Marianne, Fraser, Kathy, Kuhn, Jennifer, MacLeod, Rob , Rose, Dawn, Kim, John S. , Beinum, Amanda van , Fetzer, Susan, Clarke, France J. , Sheers, Melissa, Zytaruk, Nicole, Davis, Denise, Eaton, Catherine, Lukinuk, Connie, Wright, Angela, Khalid, Imrana, Lee, Julie, Lee, Yoon Min , Cuthbertson, Brian H. , Kaur, Navjot , Herridge, Margaret, Chen, Daniel Tzu-Hsuan , Haji, Fatima, Ming, Jie, Farias, Paulina, Kaur, Rajvinder, Pham, Tam Thi , Goel, Rakhi, Carrier, François Martin , Chassé, Michaël , Hébert, Paul, Kolan, Christophe , Boumahni, Dounia, Ghamraoui, Ali, Lebrasseur, Martine, Lorio, Stéphanie, Laforest, Louise, Lim, Sothun, Morrissette, Jennifer, Pagé, France, Dionne, Maude, Michel, Isabelle, Pépin, Alexandre, Poulin, Sandrine, Cloutier, Sylvie, Nicolson, Jessie, Paquette, Isabelle, Harvey, Johanne, Inthanavong, Lotthida, Daoust, Karine, Turgeon, Alexis F , Boivin, Anick, Breton, Sarah-Judith, Ouellet, Catherine, Grégoire, Claire, Samson, Mélanie, Lellouche, François, Khwaja, Kosar, Grushka, Jeremy Richard , Garcia, Laura, Magder, Sheldon A. , Corey, Alyssa, Mian, Jasmine, Hall, Rick, Green, Robert, Gillis, Diana, Anderson, Brenda, Brunn, Greg, Stern, Erin, Taylor, Robert, Fowler, Kim, Krause, Katie, Moore, Kaitlin , Ghanem, Alaaeldien, Hegazy, Mohamed I. , Villafranca, Marjane

Mayo Clinic

JAMA | September 21, 2021 | Volume: 326 | Issue: 11 | Pages: 1024

10.1001/jama.2021.13355 | PMID 34546300 Get It

Appropriate use criteria for ancillary diagnostic testing in dermatopathology: New recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee
Fung, Maxwell A. , Vidal, Claudia I. , Armbrecht, Eric A., Andea, Aleodor A. , Cassarino, David S. , Comfere, Nneka I. , Emanuel, Patrick O. , Ferringer, Tammie , Kim, Jinah , Lauer, Scott , Linos, Konstantinos , Missall, Tricia A. , Sundram, Uma , Panel, Rating, Calame, Antoanella , Duncan, Lyn M. , Elston, Dirk M. , Hosler, Gregory A. , Hurley, Yadira, Messina, Jane L. , Myles, Jonathan P. , Prieto, Víctor G. , Reddy, Vijaya , Schaffer, András , Subtil, Antonio , Fung, Maxwell A , Vidal, Claudia I , Cassarino, David S , Comfere, Nneka , Emanuel, Patrick O , Kim, Jinah , Linos, Konstantinos , Missall, Tricia A , Motaparthi, Kiran , Patel, Rajiv M , Sundram, Uma , Hosler, Gregory A , Hurley, Maria Yadira , Messina, Jane , Plaza, Jose Antonio , Prieto, Victor G , Subtil, Antonio , Hristov, Alexandra C. , Novoa, Roberto A. , Patel, Rajiv M. , Shalin, Sara C. , Panel, Rating, Bennett, Daniel D , Lazar, Alexander J. , Lowe, Lori , Myles, Jonathan

Mayo Clinic

Journal of Cutaneous Pathology | September 18, 2021 | Volume: 49 | Issue: 3 | Pages: 231-245

10.1111/cup.14135 | PMID 34536035 Get It

AbstractBackgroundAppropriate use criteria (AUC) provide patient‐centered physician guidance in test selection. An initial set of AUC was reported by the American Society of Dermatopathology (ASDP) in 2018. AUC reflect evidence collected at single timepoints and may be affected by evolving evidence and experience. The objective of this study was to update and expand AUC for selected tests.MethodsRAND/UCLA (RAND Corporation [Santa Monica, CA]/University of California Los Angeles) methodology used includes the following: (a) literature review; (b) review of previously rated tests and previously employed clinical scenarios; (c) selection of previously rated tests for new ratings; (d) development of new clinical scenarios; (e) selection of additional tests; (f) three rating rounds with feedback and group discussion after rounds 1 and 2.ResultsFor 220 clinical scenarios comprising lymphoproliferative (light chain clonality), melanocytic (comparative genomic hybridization, fluorescence in situ hybridization, reverse transcription polymerase chain reaction, telomerase reverse transcriptase promoter), vascular disorders (MYC), and inflammatory dermatoses (periodic acid‐Schiff, Gömöri methenamine silver), consensus by panel raters was reached in 172 of 220 (78%) scenarios, with 103 of 148 (70%) rated “usually appropriate” or “rarely appropriate” and 45 of 148 (30%), “appropriateness uncertain.” Limitations: The study design only measures appropriateness. Cost, availability, test comparison, and additional clinical considerations are not measured. The possibility that the findings of this study may be influenced by the inherent biases of the dermatopathologists involved in the study cannot be excluded.ConclusionsAUC are reported for selected diagnostic tests in clinical scenarios that occur in dermatopathology practice. Adhering to AUC may reduce inappropriate test utilization and improve healthcare delivery.
Radial Head Lag: A Possible Biomechanical Mechanism for Osteochondritis Dissecans of the Capitellum in Baseball Pitchers
Rotman, Dani , Liévano, Jorge Rojas , Hooke, Alexander W. , O’Driscoll, Shawn W. , Kwak, Jae-Man, Rojas Lievano, Jorge, Hooke, Alexander, Fitzsimmons, James S. , O'Driscoll, Shawn W., Fitzsimmons, James S , Kwak, Jae‐Man , Camp, Christopher L. , Lievano, Jorge Rojas

Mayo Clinic

The American Journal of Sports Medicine | September 15, 2021 | Volume: 49 | Issue: 12 | Pages: 3226-3233

10.1177/03635465211033971 | PMID 34523371 Get It

Background: Osteochondritis dissecans (OCD) of the capitellum is common in throwing athletes and is believed to result from repetitive overloading on the radiocapitellar (RC) joint, although the cause and mechanism remain unclear. The torsional forces (moments) generated by the triceps during elbow extension pull only on the ulna; therefore, the radial head moves passively across the capitellum and is effectively “dragged along” by the ulna. Any laxity in the proximal radioulnar joint could lead to asynchronous motion between the radius and ulna, resulting in the radial head lagging behind the coronoid and possibly malarticulating with the capitellum during such motion. Hypothesis: Radial head motion on the capitellum lags behind ulnohumeral joint motion during simulated throwing. Study Design: Controlled laboratory study. Methods: A total of 8 cadaveric elbows were tested under simulated throwing, including active extension of the elbow generated by pulling of the triceps under valgus stress, as well as during passive extension under valgus stress to serve as a reference. Ulnohumeral motion was tracked using a video camera. Radial head motion was tracked using an intra-articular, thin-film pressure sensor mounted on the capitellum, and the longitudinal movement of the center of force (COF) of the radial head was measured. Radial head motion was compared between passive and active motion for each 10° of elbow extension from 90° to 20°. Results: Elbow motion during simulated active extension reached an angular velocity of 366 deg/s. Radial head motion during simulated active extension significantly lagged compared with its motion during passive extension at every elbow extension angle examined between 70° and 20° ( P < .001). The maximal lag reached a mean of 4 mm (range, 2-7 mm). In other words, RC and ulnohumeral motion were asynchronous during simulated throwing. Conclusion: This study describes a novel phenomenon: motion of the radial head across the capitellum during rapid extension, such as in baseball pitching, lags behind that seen during passive elbow motion. According to a new proposed theory of OCD lesion development, this lag should result in RC incongruency and elevated shear forces on the capitellum due to edge loading. Clinical Relevance: We propose a new biomechanical explanation for OCD of the capitellum in baseball pitchers: radial head lag. Understanding this process is the first step in efforts to prevent this common injury.
Comparison of the real‐world effectiveness of vertical versus lateral functional hemispherotomy techniques for pediatric drug‐resistant epilepsy: A post hoc analysis of the HOPS study
Fallah, Aria , Lewis, Evan , Ibrahim, George M. , Tseng, Chi‐Hong , Harris, William B., Chen, Jia‐Shu , Lin, Kao‐Min, Cai, Lixin , Liu, Qingzhu , Lin, Jiuluan , Mathern, Gary W. , Smyth, Matthew D. , O’Neill, Brent R., Dudley, Roy , Ragheb, John , Bhatia, Sanjiv, Delev, Daniel , Ramantani, Georgia , Zentner, Josef , Dorfer, Christian , Feucht, Martha , Czech, Thomas , Bollo, Robert J. , Issabekov, Galymzhan , Zhu, Hongwei , Connolly, Mary , Steinbok, Paul , Zhang, Kai , Weiner, Howard L. , Lapalme‐Remis, Samuel , Tripathi, Manjari , Chandra, P. Sarat , Hader, Walter , Wang, Feng‐Peng , Champagne, Pierre‐Olivier , Brunette‐Clément, Tristan , Budke, Marcelo , Pérez-Jiménez, María Ángeles, Raftopoulos, Christian , Finet, Patrice, Michel, Pauline, Schaller, Karl , Malone, Christian Cantillano, Pociecha, Juan , Chamorro, Noelia, Muro, Valeria L., Lehe, Marec von , Vieker, Silvia, Oluigbo, Chima , Gaillard, William D. , Al‐Khateeb, Mashael, Alotaibi, Faisal , Krayenbühl, Niklaus , Bolton, Jeffrey , Weil, Alexander G. , Cai, Li-Xin , Ramantani, Georgia , Dorfer, Christian , Feucht, Martha , Wong-Kisiel, Lily, Tripathi, Manjari , Sarat Chandra, Poodipedi , von Lehe, Marec , Gaillard, William D , Weil, Alexander G , Fallah, Aria , Chen, Jia-Shu , Oluigbo, Chima O , Kola, Olivia , Zhou, Wen-Jing , Wang, Anthony , Zhang, Jianguo , Hidalgo, Eveline Teresa , Wong‐Kisiel, Lily C. , Wang, Feng‐Peng, Yao, Yi , Guo, Qiang , Li, Shao‐Chun, Stienen, Martin Nikolaus , Baro, Valentina , Pearl, Phillip L.

Mayo Clinic

Epilepsia | September 12, 2021 | Volume: 62 | Issue: 11 | Pages: 2707-2718

10.1111/epi.17021 | PMID 34510448 Get It

AbstractObjectiveThis study was undertaken to determine whether the vertical parasagittal approach or the lateral peri‐insular/peri‐Sylvian approach to hemispheric surgery is the superior technique in achieving long‐term seizure freedom.MethodsWe conducted a post hoc subgroup analysis of the HOPS (Hemispheric Surgery Outcome Prediction Scale) study, an international, multicenter, retrospective cohort study that identified predictors of seizure freedom through logistic regression modeling. Only patients undergoing vertical parasagittal, lateral peri‐insular/peri‐Sylvian, or lateral trans‐Sylvian hemispherotomy were included in this post hoc analysis. Differences in seizure freedom rates were assessed using a time‐to‐event method and calculated using the Kaplan–Meier survival method.ResultsData for 672 participants across 23 centers were collected on the specific hemispherotomy approach. Of these, 72 (10.7%) underwent vertical parasagittal hemispherotomy and 600 (89.3%) underwent lateral peri‐insular/peri‐Sylvian or trans‐Sylvian hemispherotomy. Seizure freedom was obtained in 62.4% (95% confidence interval [CI] = 53.5%–70.2%) of the entire cohort at 10‐year follow‐up. Seizure freedom was 88.8% (95% CI = 78.9%–94.3%) at 1‐year follow‐up and persisted at 85.5% (95% CI = 74.7%–92.0%) across 5‐ and 10‐year follow‐up in the vertical subgroup. In contrast, seizure freedom decreased from 89.2% (95% CI = 86.3%–91.5%) at 1‐year to 72.1% (95% CI = 66.9%–76.7%) at 5‐year to 57.2% (95% CI = 46.6%–66.4%) at 10‐year follow‐up for the lateral subgroup. Log‐rank test found that vertical hemispherotomy was associated with durable seizure‐free progression compared to the lateral approach (p = .01). Patients undergoing the lateral hemispherotomy technique had a shorter time‐to‐seizure recurrence (hazard ratio = 2.56, 95% CI = 1.08–6.04, p = .03) and increased seizure recurrence odds (odds ratio = 3.67, 95% CI = 1.05–12.86, p = .04) compared to those undergoing the vertical hemispherotomy technique.SignificanceThis pilot study demonstrated more durable seizure freedom of the vertical technique compared to lateral hemispherotomy techniques. Further studies, such as prospective expertise‐based observational studies or a randomized clinical trial, are required to determine whether a vertical approach to hemispheric surgery provides superior long‐term seizure outcomes.
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
Herrmann, Joerg , Lenihan, Daniel J. , Armenian, Saro H. , Barac, Ana , Blaes, Anne , Cardinale, Daniela , Carver, Joseph R. , Dent, Susan , Ky, Bonnie , Lyon, Alexander R. , Fradley, Michael G. , Ganatra, Sarju , Curigliano, Giuseppe , Mitchell, Joshua D. , Minotti, Giorgio , Lang, Ninian N. , Liu, Jennifer E. , Neilan, Tomas G. , O’Quinn, Rupal, Pusic, Iskra , Porter, Charles , Reynolds, Kerry L. , Ruddy, Kathryn J. , Valent, Peter , Lenihan, Daniel , Armenian, Saro H , Carver, Joseph , López-Fernández, Teresa , Fradley, Michael G , Ganatra, Sarju , Curigliano, Giuseppe , Mitchell, Joshua D , Minotti, Giorgio , Lang, Ninian N , Nohria, Anju , Porter, Charles , Thavendiranathan, Paaladinesh , Barac, Ana , Blaes, Anne H , Ky, Bonnie , Valent, Peter , Lyon, Alexander R , López‐Fernández, Teresa , Dent, Susan

Mayo Clinic

European Heart Journal | September 10, 2021 | Volume: 43 | Issue: 4 | Pages: 280-299

10.1093/eurheartj/ehab674 | PMID 34904661 Get It

Abstract The discipline of Cardio-Oncology has seen tremendous growth over the past decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the mitigation and management of CV complications or toxicities of cancer therapies, which can have profound implications on prognosis. To that effect, many studies have assessed CV toxicities in patients undergoing various types of cancer therapies; however, direct comparisons have proven difficult due to lack of uniformity in CV toxicity endpoints. Similarly, in clinical practice, there can be substantial differences in the understanding of what constitutes CV toxicity, which can lead to significant variation in patient management and outcomes. This document addresses these issues and provides consensus definitions for the most commonly reported CV toxicities, including cardiomyopathy/heart failure and myocarditis, vascular toxicity, and hypertension, as well as arrhythmias and QTc prolongation. The current document reflects a harmonizing review of the current landscape in CV toxicities and the definitions used to define these. This consensus effort aims to provide a structure for definitions of CV toxicity in the clinic and for future research. It will be important to link the definitions outlined herein to outcomes in clinical practice and CV endpoints in clinical trials. It should facilitate communication across various disciplines to improve clinical outcomes for cancer patients with CV diseases.
Addressing the Elephant in the Intensive Care Unit: The Role of Interprofessional Education
Gary, Phillip , Niven, Alexander S. , Niven, Alexander S , Dong, Yue

Mayo Clinic

ATS Scholar | September 8, 2021 | Volume: 2 | Issue: 3 | Pages: 293-296

10.34197/ats-scholar.2021-0100ed | PMID 34667978 Get It

Clinical and Infection Prevention Applications of Severe Acute Respiratory Syndrome Coronavirus 2 Genotyping: An Infectious Diseases Society of America/American Society for Microbiology Consensus Review Document
Greninger, Alexander L. , Bard, Jennifer Dien , Colgrove, Robert C. , Hayden, Mary K. , Humphries, Romney M. , Lowe, Christopher F. , Pillai, Dylan R. , Rhoads, Daniel D. , Yao, Joseph D. , Lee, Francesca M, Graf, Erin H. , Humphries, Romney , Rhoads, Daniel D , Greninger, Alexander L , Hanson, Kimberly E. , Miller, Melissa B.

Mayo Clinic

Clinical Infectious Diseases | September 8, 2021 | Volume: 74 | Issue: 8 | Pages: 1496-1502

10.1093/cid/ciab761 | PMID 34731234 Get It

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged into a world of maturing pathogen genomics, with &gt;2 million genomes sequenced at this writing. The rise of more transmissible variants of concern that affect vaccine and therapeutic effectiveness has led to widespread interest in SARS-CoV-2 evolution. Clinicians are also eager to take advantage of the information provided by SARS-CoV-2 genotyping beyond surveillance purposes. Here, we review the potential role of SARS-CoV-2 genotyping in clinical care. The review covers clinical use cases for SARS-CoV-2 genotyping, methods of SARS-CoV-2 genotyping, assay validation and regulatory requirements, clinical reporting for laboratories, and emerging issues in clinical SARS-CoV-2 sequencing. While clinical uses of SARS-CoV-2 genotyping are currently limited, rapid technological change along with a growing ability to interpret variants in real time foretell a growing role for SARS-CoV-2 genotyping in clinical care as continuing data emerge on vaccine and therapeutic efficacy.
Hallmarks of RET and Co-occuring Genomic Alterations inRET-aberrant Cancers
Adashek, Jacob J. , Desai, Aakash , Andreev-Drakhlin, Alexander , Roszik, Jason , Cote, Gilbert J. , Subbiah, Vivek , Desai, Aakash P , Subbiah, Vivek

Mayo Clinic

Molecular Cancer Therapeutics | September 7, 2021 | Volume: 20 | Issue: 10 | Pages: 1769-1776

10.1158/1535-7163.mct-21-0329 | PMID 34493590 Get It

AbstractActivating receptor-tyrosine kinase rearranged during transfection (RET) mutations and fusions are potent drivers of oncogenesis. The recent FDA approvals of highly potent and selective RET inhibitors, selpercatinib and pralsetinib, has altered the therapeutic management of RET aberrant tumors. There is ample evidence of the role of RET signaling in certain cancers. RET aberrations as fusions or mutations occur in multiple cancers, however, there is considerable phenotypic diversity. There is emerging data on the lack of responsiveness of immunotherapy in RET-altered cancers. Herein, we review the registrational data from the selective RET-inhibitor trials, and comprehensively explore RET alterations in pan-cancer adult malignancies and their co-alterations. These co-occuring alterations may define the future of RET inhibition from specific selective targeting to customized combination therapies as data are rapidly emerging on both on-target and off-target acquired resistance mechanisms. Fascinatingly, oncogenic RET fusions have been reported to mediate resistance to EGFR inhibition and KRASG12C inhibition.
Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler
Bergholtz, Helga , Carter, Jodi M. , Cesano, Alessandra, Cheang, Maggie C.U. , Church, S. , Divakar, Prajan , Fuhrman, Christopher A. , Goel, Shom , Gong, Jingjing , Guerriero, Jennifer L. , Hoang, Margaret L. , Hwang, E. Shelley , Kuasne, Hellen, Lee, Jinho , Liang, Yan , Perez, Jessica, Prat, Aleix , Pusztai, Lajos , Reeves, Jason , Riazalhosseini, Yasser , Richer, Jennifer K. , Şahin, Özgür , Sato, Hiromi , Sørlie, Thérese , Swarbrick, Alexander , Thompson, E. Aubrey , Tolaney, Sara M. , Warren, Sarah H. , Cheang, Maggie Chon U , Church, Sarah E , Prat, Aleix , Pusztai, Lajos , Sahin, Özgür , Sørlie, Therese , Liang, Yan , Carter, Jodi , Mittendorf, EA , Schlam, Ilana Miriam , Stover, Daniel G. , Swain, Sandra M. , Warren, Sarah

Mayo Clinic

Cancers | September 6, 2021 | Volume: 13 | Issue: 17 | Pages: 4456

10.3390/cancers13174456 | PMID 34503266 Get It

Breast cancer is a heterogenous disease with variability in tumor cells and in the surrounding tumor microenvironment (TME). Understanding the molecular diversity in breast cancer is critical for improving prediction of therapeutic response and prognostication. High-plex spatial profiling of tumors enables characterization of heterogeneity in the breast TME, which can holistically illuminate the biology of tumor growth, dissemination and, ultimately, response to therapy. The GeoMx Digital Spatial Profiler (DSP) enables researchers to spatially resolve and quantify proteins and RNA transcripts from tissue sections. The platform is compatible with both formalin-fixed paraffin-embedded and frozen tissues. RNA profiling was developed at the whole transcriptome level for human and mouse samples and protein profiling of 100-plex for human samples. Tissue can be optically segmented for analysis of regions of interest or cell populations to study biology-directed tissue characterization. The GeoMx Breast Cancer Consortium (GBCC) is composed of breast cancer researchers who are developing innovative approaches for spatial profiling to accelerate biomarker discovery. Here, the GBCC presents best practices for GeoMx profiling to promote the collection of high-quality data, optimization of data analysis and integration of datasets to advance collaboration and meta-analyses. Although the capabilities of the platform are presented in the context of breast cancer research, they can be generalized to a variety of other tumor types that are characterized by high heterogeneity.